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Abstract
Background: Plants have long been investigated as a source of antibiotics and other bioactives for the treatment of 
human disease. New Zealand contains a diverse and unique flora, however, few of its endemic plants have been used 
to treat tuberculosis. One plant, Laurelia novae-zelandiae, was reportedly used by indigenous Maori for the treatment of 
tubercular lesions.
Methods: Laurelia novae-zelandiae and 44 other native plants were tested for direct anti-bacterial activity. Plants were 
extracted with different solvents and extracts screened for inhibition of the surrogate species, Mycobacterium 
smegmatis. Active plant samples were then tested for bacteriostatic activity towards M. tuberculosis and other clinically-
important species.
Results: Extracts of six native plants were active against M. smegmatis. Many of these were also inhibitory towards M. 
tuberculosis including Laurelia novae-zelandiae (Pukatea). M. excelsa (Pohutukawa) was the only plant extract tested that 
was active against Staphylococcus aureus.
Conclusions: Our data provide support for the traditional use of Pukatea in treating tuberculosis. In addition, our 
analyses indicate that other native plant species possess antibiotic activity.
Background
Tuberculosis (TB) is the leading cause of death due to a
single infectious organism [1]. In 2007, 1.78 million peo-
ple died from the disease and an estimated 9.27 million
new cases were recorded worldwide [2]. TB requires a
lengthy treatment period of six months with the first-line
drugs rifampicin, isoniazid, ethambutol and pyrazin-
amide [3]. The availability of new drugs that shortened
the course of chemotherapy would improve patient
adherence and affordability thus, enabling more favour-
able treatment outcomes. In addition, alternative drugs
are needed to counteract the spread of drug resistant TB
which threatens global control programmes [4]. MDR-
TB, resistant to rifampicin and isoniazid, now exceeds 0.5
million cases per year [2] and in some states accounts for
up to 22% of TB cases [2,5]. Extensively-drug resistant
(XDR) strains of M. tuberculosis, resistant to both first-
and second-line drugs, were first reported in the United
State, Latvia and South Korea in 2006 [6] but are now
present in 57 countries [7].
The World Health Organisation has advised that new
TB drugs are required to treat TB [8,9]. While much of
the focus has been on screening libraries of synthetic
compounds for mycobacterial inhibitors, plants have
often provided a source of anti-bacterial compounds. For
example, Aegicerin, isolated from Clavija procera, has
been shown to have activity against Mycobacterium
tuberculosis  H37Rv and MDR-TB strains [10]. Rho-
domyrtone, a compound from the Southeast Asian plant
Rhodomyrtus tomentosa was found to have potent anti-
bacterial activity against a number of clinically-important
Gram-positive species including Enterococcus faecalis,
Streptococcus pneumoniae and methicillin-resistant
Staphylococcus aureus (MRSA) [11].
In this work, solvent extracts were prepared from 45
native New Zealand plants and screened for activity using
Mycobacterium smegmatis. Active samples were then
tested against Mycobacterium bovis BCG, M. tuberculosis
H37Ra,  Escherichia coli and  Staphylococcus aureus. A
n u m b e r  o f  p l a n t s  w e r e  i d e n t i f i e d  a s  c o n t a i n i n g  a n t i -
Mycobacterium tuberculosis activity and their potential
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for generating novel compounds for the treatment of
tuberculosis is discussed.
Methods
Bacterial strains and plasmids
The mycobacterial strains used were Mycobacterium
smegmatis  mc  2155,  M. bovis BCG (Pasteur) and M.
tuberculosis  H37Ra.  M. smegmatis and  M. bovis BCG
were labelled with GFP through the introduction of the
plasmid pSHIGH+hsp60 by electroporation and selection
on media containing 50 μg/ml kanamycin as previously
described [12]. GFP-labelled Staphylococcus aureus New-
man was constructed as follows: the fdh (formate dehy-
drogenase) promoter was amplified from S. aureus
Newman using Phusion™ Flash High-Fidelity PCR Master
Mix (Finnzymes, Finland) according to the manufactur-
ers' instructions with primers GGGGACAACT
TTGTATAGAAAAGTTGgaaggggtaagtgtgataagc and
GGGGACTGCTTTTTTGTACAAACTTgtctttaaaataag
aagttcattaattgttc, where uppercase represents attB sites
for Gateway cloning (Invitrogen) and lower case repre-
sents S. aureus DNA. The 275 bp amplified product was
cloned into pDONR221 using BP Clonase™ II (Invitrogen)
and used to transform chemically-competent Escherichia
coli TOP 10 (Invitrogen). The insert was sequenced to
confirm an error-free amplification. Gateway cloning
with LR Clonase™ II (Invitrogen) combined the fdh pro-
moter with gfp, or gfpluxABCDE, and the rrnBT1T2 ter-
minator in the destination vector pDEST-pUNK1 as
described previously [13]. The correct plasmid constructs
from bioluminescent/fluorescent LR-reaction transfor-
mants of E. coli TOP 10 were confirmed by restriction
mapping. The plasmids generated were electroporated
into S. aureus RN4220 as previously described [14] and
then transferred to S. aureus Newman by bacteriophage
transduction [15]. S. aureus strains containing pDEST-
pUNK1 derivatives were selected on media containing 30
g/ml erythromycin. Escherichia coli DH5α was labelled
with GFP using pOT11 [16].
Plant Collection and solvent extraction
Plant samples were collected from the Karori Wildlife
Sanctuary (Zealandia) and the Otari-Wilton Bush
Reserve, Wellington; Kaitoke Regional Park, Upper Hutt;
and the Nelson region with permission. The native New
Zealand plants tested for anti-mycobacterial activity are
listed in Table 1. Plant samples were collected fresh, mac-
erated and dried in a desiccator. For each sample, approx-
imately 1 g of dried plant tissue was placed in a 50 ml
conical tube. Sterile distilled water, ethanol or methanol
were added to the samples to give a final concentration of
100 mg/ml. The samples were incubated in a water bath
at 55°C for 1 hour and then stored at -80°C. The incuba-
tion at 55°C was used as Ma ¯ori heated plant extracts dur-
ing the preparation of some traditional medicines. The
resulting crude extracts were sterilized using a 0.22 μm
filter prior to anti-microbial analysis.
Screening plant extracts for bacteriostatic activity towards 
M. smegmatis
Plant extracts were tested for bacteriostatic activity in a
96 well-plate format assay using M. smegmatis mc 2155/
pSHIGH+hsp60 as previously described [12]. Optical
Density (OD) and GFP fluorescence were used to detect
growth inhibition. M. smegmatis was cultured for 24
hours in Luria Broth (LB) supplemented with D-arabi-
nose (1 mg/ml), Tween 80 (0.1% v/v) and kanamycin (50
μg/ml). Sterile distilled water (150 μL) was added to the
outer lanes of the 96-well microtiter plates to minimise
evaporation. Liquid media (50 μL) was added to the
remaining wells. The effect of the solvents used on the
growth of M. smegmatis was tested. Inhibition of M.
smegmatis growth was observed at concentrations of eth-
anol and methanol greater than 5% (v/v). Plant extracts
were added to columns 2 and 3 of the microtitre plates
with a starting concentration of 2 mg/ml corresponding
to a solvent concentration of 2% (v/v). A two-fold serial
dilution was then performed on each extract starting at
column 3. M. smegmatis cells were added to rows B-D at
a final OD at 600 nm (OD 600) of 0.2. Rows E-G contained
media and extract alone, to measure any background
optical density or fluorescence associated with the
extract. A number of controls were added to ensure assay
reliability, including the use of standard anti-tubercular
drugs, rifampicin and streptomycin, as positive controls,
each starting at a concentration of 100 μM. All extracts
and controls were tested in triplicate. Plates were sealed
and incubated at 37°C with 200 rpm shaking for 96 hours,
after which the plates were read for OD and GFP fluores-
cence. For active extracts, dose response experiments
were performed to validate activity versus M. smegmatis.
Bacteriostatic assays for M. bovis, M. tuberculosis, S. aureus 
and E. coli
M. bovis BCG and M. tuberculosis H37Ra cultures were
grown in Middlebrook 7H9 broth supplemented with
10% (v/v) OADC (0.06% oleic acid, 5% BSA, 2% Dextrose,
0.85% NaCl), glycerol (0.5% v/v) and Tween 80 (0.05% v/
v). A bacteriostatic assay was set up as previously
described [12], with cells added to give a final OD 600 of
0.05 . All extracts and controls were tested in triplicate.
Plates were sealed and incubated at 37°C with 200 rpm
shaking for 14 days before the GFP fluorescence and/or
OD of the cultures were measured.
GFP-labelled  S. aureus N e w m a n  w a s  c u l t u r e d  i n  L B
containing erythromycin (30 μg/ml) and xylose (0.5% w/
v). GFP-labelled E. coli DH5α/pOT11 was cultured in LB
containing chloramphenicol (25 μg/ml). IPTG (100 μg/Earl et al. BMC Complementary and Alternative Medicine 2010, 10:25
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Table 1: Native New Zealand plants screened for activity against M. smegmatis.
Plant name (common) Part Documented Traditional Medicinal Use
Adiantum raddianum (Delta maidenhair 
fern)
Leaf ni
Agathis australis (Kauri) Leaf ni
Arthropodium cirratum (New Zealand rock 
lily)
Leaf Ulcers [29]
Asplenium bulbiferum (Hen and chicken 
fern)
Leaf ni
Beilschmiedia tawa (Tawa) Leaf Sore throat, colds, cough [22]
Blechnum fluviatile (Kiwikiwi) Leaf Sore tongue and mouth [30]
Brachyglottis repanda (Rangiora) Leaf Wounds, ulcers and boils [30]
Carpodetus serratus (Marble leaf) Leaf ni
Clianthus puniceus (Kakabeak) Leaf ni
Cordyline australis (Cabbage tree) Leaf Dysentery, diarrhoea and sores [30]
Cortaderia toetoe (Toetoe) Shoot Diarrhoea, bladder complaints [23,31]
Cyathea dealbata (Ponga) Fronds Treat boils [32]
Dacrydium cupressinum (Rimu) Leaf Treat sores [22]
Dracophyllum longifolium (Inanga) Leaf ni
Dodonaea viscosa (Ake ake) Leaf Treat sore throats and skin irritations [33]
Dysoxylum spectabile (Kohekohe) Leaf Relieve coughing, colds and fevers [33]
Exocarpus bidwilli Leaf ni
Seed ni
Hebe stricta (Koromiko) Leaf Skin problems, ulcers, diarrhoea, dysentery, kidney and bladder complaints 
[33]
Flower ni
Hymenophyton flabellatum (Liverwort) Leaf ni
Knightia excelsa (Rewarewa) Leaf Relieve coughing [22]
Kunzea ericoides (Kanuka) Leaf Relieve pain, headaches and coughs [22]
Laurelia novae-zelandiae (Pukatea) Inner 
bark
Sores, ulcers, toothache and tuberculosis [23,30,32]
Bark Treat sores, skin conditions, venereal disease [29]
Leaf Toothache [22]
Leptospermum scoparium (Manuka) Leaf Colds, pains, urinary troubles [30]
Flower ni
Lophomyrtus bullata (Ramarama) Leaf Treat bruises [22]
Macropiper excelsum (Kawakawa) Leaf Rheumatism, arthritis, diuretic, bruises and chest difficulties [32,34]
Melicytos ramiflorus (Mahoe) Leaf Treat rheumatism and stomach wounds [30]
Meryta sinclairii (Puka) Leaf ni
Metrosideros excelsa (Pohutukawa) Leaf ni
Flower Sore throats [23,30]
Metrosideros robusta (Northern Rata) Leaf ni
Metrosideros umbellata (Southern Rata) Leaf ni
Myoporum laetum (Ngaio) Leaf Bruises and infected wounds [30]
Leaf Bruises and wounds
Nothofagus fusca (Red beech) Leaf ni
Paesia scaberula (Lace fern) Leaf niEarl et al. BMC Complementary and Alternative Medicine 2010, 10:25
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ml) was added to induce GFP expression. The bacterio-
static assay for S. aureus and E. coli were performed as
per the M. smegmatis bacteriostatic assay method except
cultures were incubated for 24 hours at 37°C with 200
rpm shaking post addition of extracts.
Determination of inhibitory concentrations of plant 
extracts
A Perkin Elmer Envision 2102 multilabel plate reader and
the Wallace Envision Manager 1.12 software program
were used to measure the OD and GFP signals of the
microtitre plate cultures. OD was measured at 600 nm.
GFP fluorescence was detected using excitation and
emission wavelengths of 485 nm and 510 nm, respec-
tively. 12-point scans were performed on each well to
minimise intra-well variation. The intrinsic absorbance
and fluorescence readings of extracts alone were mea-
sured to account for background signal and subtracted
from the readings for the test samples. Data were norma-
lised by expressing the absorbance and fluorescence val-
ues as a percentage of a no-drug negative control. Dose-
response curves were plotted using SigmaPlot (version
10.0) and minimum inhibitory concentration (MIC) and
50% inhibitory concentration (IC 50) values were calcu-
lated.
Results
Activity of plant extracts towards M. smegmatis
45 plants native to New Zealand (Table 1) were extracted
with water, ethanol and methanol and the extracts were
tested for their ability to inhibit the growth of the fast-
growing species, M. smegmatis. Extracts from 6 plants
species, Laurelia novae-zelandiae, Lophomyrtus bullata,
Metrosideros excelsa,  Myoporum laetum,  Pittosporum
tenuifolium and Pseudopanax crassifolius showed inhibi-
tion towards M. smegmatis (Table 2). Dose-response
experiments were performed on the active extracts and
their MIC and IC 50 values were determined. The most
active extract was derived from L. novae-zelandiae
(Pukatea). The bark of L. novae-zelandiae generated an
IC 50 value of 0.02 mg/ml, respectively while the cambium
had an IC 50 of 0.25 mg/ml (Table 3). Significant activity
was also observed with respect to the leaf, IC 50 of 0.11
mg/ml, and flower, IC 50 of 0.41 mg/ml, of M. excelsa. The
leaf of P. tenuifolium was less active with an IC 50 value of
0.78 mg/ml (Table 3).
Antibacterial activity of plant extracts towards clinically-
relevant species
The extracts of L. novae-zelandiae, L. bullata, M. excelsa,
M. laetum, P. tenuifolium and P. crassifolius were tested
against M. bovis BCG and M. tuberculosis H37Ra. The
leaf of P. tenuifolium was the most active extract with
respect to M. tuberculosis with an IC 50 of 0.51 mg/ml
(Table 3). The bark taken from L. novae-zelandiae had an
IC 50 of 0.54 mg/ml against M. bovis and an IC 50 of 2.39
mg/ml against M. tuberculosis (Table 3). The cambium of
L. novae-zelandiae was similarly active against both M.
bovis and M. tuberculosis. The leaf extract from M. lae-
tum was not active against M. tuberculosis. To examine
the specificity of the anti-bacterial activity of the plant
extracts, the extracts were also tested against S. aureus
and E. coli. The leaf of M. excelsa which was active
against M. smegmatis and to a lesser extent, M. tuberculo-
sis, also displayed antibacterial activity towards S. aureus
with an IC 50 of 1.17 mg/ml. None of the extracts tested
exhibited anti-bacterial activity towards E. coli up to the
10 mg/ml concentration tested.
Phormium tenax (New Zealand flax) Leaf Treat cuts and constipation [28]
Pittosporum tenuifolium (Kohuhu) Leaf Eczema and other skin diseases, fever and chills [22]
Plagiochila stephensoniana (Liverwort) Leaf ni
Pseudopanax arboreus (Five finger) Leaf ni
Pseudopanax crassifolius (Lancewood) Leaf ni
Pteridium esculentum (Bracken) Leaf Antiseptic, treats sores [33]
Rubus cissoides (Bush lawyer) Leaf Chest congestion, coughs and sore throats [30]
Schefflera digitata (Seven finger) Leaf ni
Sophora microphylla (Kowhai) Leaf Wounds, back, abdominal and internal pains [32]
Urtica ferox (Stinging nettle) Leaf ni
Vitex lucens (Puriri) Leaf Backache, ulcers, and sore throats [30]
Weinmannia racemosa (Kamahi) Leaf ni 
ni = no information available.
Table 1: Native New Zealand plants screened for activity against M. smegmatis. (Continued)Earl et al. BMC Complementary and Alternative Medicine 2010, 10:25
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Discussion
Plants and their extracts have been used by indigenous
peoples for the treatment of infectious diseases such as
tuberculosis since long before the discovery of antibiot-
ics. A recent study determined that more than 80 plant
species have been used by traditional medical practitio-
ners in Uganda to treat tuberculosis [17]. Another study
characterised leaf, bark and root material from trees used
as traditional anti-tubercular medicines in South Africa.
Direct bacteriostatic activity towards Mycobacterium
aurum was identified for Acacia nilotica and Combretum
kraussii at concentrations ranging from 1.56 to 0.195 mg/
ml [18]. A survey of the ethnobotanical literature was
used to select plants used by traditional healers in Mexico
to test for activity towards M. tuberculosis. Extracts of
Citrus aurantifolia, C. sinensis and Olea europaea were
found to be active against both drug-susceptible and
drug-resistant strains of virulent M. tuberculosis with
minimum inhibitory concentrations of between 0.1 and
0.025 mg/ml [19]. Although, the New Zealand shrub
Lophomyrtus bullata (Ramarama) has been identified as
having activity towards Bacillus subtilis [20], to current
knowledge, Pukatea or other New Zealand plants have
not been assayed for activity against mycobacteria [21].
In New Zealand, the bark of Laurelia novae-zelandiae
(Pukatea) (Figure 1A) was used by Ma ¯ori in a number of
medicinal remedies but it was especially noted for its use
against tubercular lesions [22,23]. The pulp of the cam-
bium was boiled in water and the resulting liquid used for
treating tubercular ulcers. The timber of Pukatea was also
used by Ma ¯ori to create figureheads for canoes [24].
Pukatea is generally found in lowland forests in the North
Table 2: Anti-bacterial activity of plant extracts towards M. smegmatis mc2155.
Plant species Common Name Part Sample ocation Extract
Aqueous Ethanol Methanol
Laurelia novae-zelandiae Pukatea Bark Otari-Wilton + - -
Cambium Otari-Wilton - - +
Lophomyrtus bullata Ramarama Leaf Otari-Wilton - - +
Metrosideros excelsa Pohutukawa Leaf Ngaio - - +
Flower Ngaio - + -
Myoporum laetum Ngaio Leaf Ngaio + - -
Pittosporum tenuifolium Kohuhu Leaf Ngaio - + -
Pseudopanax crassifolius Lancewood Leaf Otari-Wilton - - +
'+' indicates ≥ 90% inhibition of M. smegmatis growth at a concentration of 2 mg/ml or lower.
Table 3: MIC and IC50 values of active plant extracts with respect to M. smegmatis and clinically-relevant bacterial species.
Plant Part M. smegmatis M. bovis M. tuberculosis S. aureus
mg/ml mg/ml mg/ml mg/ml
MIC IC50 MIC IC50 MIC IC50 MIC IC50
L. novae-zelandiae Bark 0.04 0.02 ± 0.01 1.50 0.54 ± 0.03 4.16 2.39 ± 0.33 > 10 > 10
Cambium 0.50 0.25 ± 0.01 2.50 1.63 ± 0.21 3.75 1.86 ± 0.22 > 10 > 10
L. bullata Leaf 1.00 0.31 ± 0.15 3.12 2.59 ± 0.43 6.51 5.59 ± 0.32 > 10 > 10
M. excelsa Leaf 0.63 0.11 ± 0.06 8.35 6.95 ± 3.07 > 10 4.83 ± 0.43 2.20 1.17 ± 0.39
Flower 0.63 0.41 ± 0.06 3.13 1.12 ± 0.12 4.18 2.19 ± 0.76 > 10 > 10
M. laetum Leaf 0.63 0.34 ± 0.02 > 10 > 10 > 10 > 10 > 10 > 10
P. tenuifolium Leaf 2.00 0.78 ± 0.34 > 10 5.37 ± 1.35 1.25 0.51 ± 0.11 > 10 > 10
P. crassifolius Leaf 0.63 0.31 ± 0.01 6.25 4.08 ± 1.76 3.58 1.74 ± 0.18 > 10 > 10
MIC, minimum inhibitory concentration. IC50, 50% inhibitory concentration.Earl et al. BMC Complementary and Alternative Medicine 2010, 10:25
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Island and the northern areas of the South Island [25]. It
can grow up to 35 metres and produces plank buttresses
(Figure 1B) to support the tree's growth in swamp or shal-
low-soil areas [25]. Pukatea has so-called 'toothed' leaves
(Figure 1C) and produces small flowers [25].
In this work, we characterised Pukatea and 44 other
native plants for activity towards M. smegmatis. Extracts
from six New Zealand plants were found to have activity
against M. smegmatis. Bark and cambium samples from
Pukatea were the most active against M. smegmatis
(Table 3). Furthermore, the bark and cambium extracts
were also active against M. tuberculosis. The direct anti-
mycobacterial activity of the Pukatea extract therefore
correlates with the use of this plant by Ma ¯ori to treat
tubercular lesions. This strengthens the possibility that
the bark of Pukatea contains previously-unknown anti-
tubercular compound(s). In Ma ¯ori medicine, M. excelsa
was used in the treatment of sore throats. Although the
traditional use of M. excelsa does not include the treat-
ment of tuberculosis, extracts from M. excelsa were nev-
ertheless active against M. smegmatis and  M.
tuberculosis. Similarly, the leaf of P. tenuifolium, used by
Ma ¯ori to treat skin infections, was active against M. smeg-
matis and M. tuberculosis. The anti-mycobacterial activi-
ties that were detected for M. excelsa and P. tenuifolium
extracts could relate to their traditional use in anti-infec-
tive therapy. Of the extracts shown to have anti-mycobac-
terial activity, only the M. excelsa leaf extract displayed
activity against S. aureus. Interestingly, none of the plant
species tested exhibited antibacterial activity towards E.
coli. It should be noted that the MIC and IC 50 values of
the extracts in the different mycobacteria (Table 3) will be
subject to variation due to species differences, the type of
growth medium used, and the assay incubation time.
There is growing interest in identifying the compounds
responsible for the anti-mycobacterial activity of tradi-
tional medicines and developing them as potential new
tuberculosis drugs. Although the chemical basis for the
anti-tubercular activity of Pukatea needs to be elucidated,
earlier chemical studies identified a novel alkaloid,
pukateine, from the bark of Pukatea. Pukateine is an anal-
gesic which acts as a D 2 dopamine receptor agonist and
α1 adrenergic receptor antagonist [26,27]. A number of
the other plant extracts found to have activity against
mycobacteria have also been analysed chemically. The
flower of M. excelsa contains ellagic acid which is a poly-
phenol antioxidant [28]. Bullatenone, discovered in L.
bullata  (Ramarama), is an antiseptic [28]. Chemical
derivatives of bullatenone have been found to have anti-
microbial properties against Bacillus subtilis [20].
Ngaione, a hepatotoxic sesquiterpene, found in the leaves
of M. laetum (Ngaio) has been used in the treatment of
athletes foot [28]. It is possible that compounds such as
pukateine, ellagic acid, bullatenone or ngaione may con-
tribute to the anti-bacterial activity of their plant extracts.
These compounds offer a starting point for future studies
to characterise the chemical basis of the anti-bacterial
activity of L. novae-zelandiae, M. excelsa, L. bullata and
M.laetum. They may also assist in identifying ways to
improve the efficiency of the extraction of anti-mycobac-
terial activity from the plant samples and hence, provide
extracts with lower MIC values towards M. tuberculosis.
Such extracts will be integral to any bioassay-guided puri-
fication of active compounds.
Conclusions
It is estimated that less than 10% of the Earth's higher
plant species have been analysed for any kind of bioactiv-
ity [18]. T here is a need for more research to be con-
d u c t e d  o n  p l a n t s  t h a t  h a v e  b e e n  t r a d i t i o n a l l y  u s e d  b y
indigenous peoples to treat tuberculosis, for the identifi-
cation of new anti-tubercular drugs. New Zealand has a
diverse flora which potentially offers many unique bioac-
tive compounds. Drawing on knowledge from traditional
medicine, we have identified a number of native plants
which contain activity against M. tuberculosis. Determin-
ing the chemical species responsible for this activity will
be the subject of further studies.
Competing interests
The authors declare that they have no competing interests.
Figure 1 Images of Laurelia novae-zelandiae (Pukatea) specimen 
located at Otari-Wilton Bush, Wellington. A, branchless trunk and 
canopy of Pukatea. B, plank buttress of Pukatea. C, examples of 
"toothed" leaves of Pukatea.Earl et al. BMC Complementary and Alternative Medicine 2010, 10:25
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